Davendra Sohal, MD of Cleveland Clinic discusses the treatment trends for pancreatic cancer, which include understanding the mechanisms of resistance to current therapies. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: Editor
Davendra Sohal, MD of Cleveland Clinic discusses the impact of perioperative chemotherapy on management of resectable pancreatic cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. TPS4152: Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Davendra Sohal, MD of Cleveland Clinic gives an overview of his presentation, Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma, which was discussed at the 2017 ASCO Annual Meeting in Chicago, IL. TPS4152: Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center discusses the impact of the talimogene laherparepvec and ipilimumab combination in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9509: Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center talks of his hopes for the expansion of talimogene laherparepvec across multiple cancer types for future clinical research. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center discusses the most exciting and interesting presentations coming out of ASCO 2017, which include three oral presentations, focusing on the efficacy of FDA-approved combination regiments in melanoma patients who have brain metastases. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center talks of the common questions most physicians ask regarding his study on talimogene laherparepvec and ipilimumab in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9509: Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center gives an overview of his presentation which focused on the use of talimogene laherparepvec and ipilimumab versus ipilimumab alone in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9509: Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma
Bernardo H. Goulart, MD, MS of Seattle Cancer Care Alliance explains the impact of natural language processing (NLP) on future clinical practice and trials. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 6528: Validation of natural language processing (NLP) for automated ascertainment of EGFR and ALK tests in SEER cases of non-small cell lung cancer (NSCLC).
Bernardo H. Goulart, MD, MS of Seattle Cancer Care Alliance discusses the use of natural language processing (NLP) for patients with non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 6528: Validation of natural language processing (NLP) for automated ascertainment of EGFR and ALK tests in SEER cases of non-small cell lung cancer (NSCLC).
Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center gives an overview of his current clinical studies, which focus on the use of mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer patients Abstract 5547: Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts Abstract TPS5607: FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FR?)-positive, platinum-resistant…
Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center discusses a collaborated study with Dr. Dr. Jalid Sehouli of AGO and Charité Campus Virchow-Klinikum, Berlin, Germany, that focuses on the clinical characteristics of long-term ovarian cancer survivors. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract e17063: Clinical characterization of long term survivors (LTS) in ovarian cancer (OC): Results of a propensity score matched (PSM) analysis of the international prospective tumor bank for ovarian cancer (TOC Network)
Michael J. Birrer, MD, PhD discusses his role as newly appointed director for the University of Alabama at Birmingham Comprehensive Cancer Center and his future plans and goals for the hospital. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center gives an overview of presentation that involves the use of avelumab in patients with endometrial cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract TPS5615: Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and POLE-mutated recurrent or persistent endometrial cancer
Manmeet S. Ahluwalia, MD of Cleveland Clinic discusses three abstracts presented at ASCO 2017, highlighting the management of brain metastases in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9506: COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600mutant (mut) melanoma brain metastases (MBM) presented by Dr. Michael A. Davies of MD Anderson Cancer Center Abstract 9507: Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204 presented by…
Manmeet S. Ahluwalia, MD of Cleveland Clinic gives an overview of his presentation, What Drives Patient Outcomes in Brain Metastases: Number, Volume, or Biology, which was discussed at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 2071: What Drives Patient Outcomes in Brain Metastases: Number, Volume, or Biology?
Vivek Subbiah, MD of MD Anderson Cancer Center discusses the impact of his study of vemurafenib in NSCLC patients on clinical practice and future clinical research. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9074: Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600mutation.
Vivek Subbiah, MD of MD Anderson Cancer Center discusses the exciting and new data presented at ASCO, which shows promise for the future of precision oncology and personalized therapy. This was recorded at the 2017 ASCO Annual Meeting.
Vivek Subbiah, MD of MD Anderson Cancer Center gives an overview of his presentation, which focused on the use of vemurafenib in patients with non small-cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9074: Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600mutation.
Alan P. Venook, MD of UCSF Helen Diller Family Comprehensive Cancer Center gives an overview of his presentation, which focused on the difference between left and right sided tumors in patients with colon cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Alan P. Venook, MD of UCSF Helen Diller Family Comprehensive Cancer Center gives an overview of the exciting presentations discussed at ASCO this year. One particular presentation he is most interested in focuses on the treatment of stage III colon cancer with adjuvant therapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Mizuki Nishino, MD, MPH of Dana-Farber Cancer Institute discusses the common questions and concerns regarding her presentation on commercially prescribed PD-1 inhibitors in non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Mizuki Nishino, MD, MPH of Dana-Farber Cancer Institute gives an overview of her presentation, Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting, which was presented at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9087: Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting.
Mizuki Nishino, MD, MPH of Dana-Farber Cancer Institute discusses the treatment trends for lung cancer and oncology overall, which include combination therapy and immune checkpoint inhibitors. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Alok Khorana, MD of Cleveland Clinic gives an overview his presentation, which focuses on time to initiating (TTI) cancer therapy for common solid tumors. Data suggests an increase in TTI is associated with substantial increase in mortality. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 6557: Time To Initiating Cancer Therapy Is Increasing And Associated With Worsened Survival In Curative Settings: A US Analysis of Common Solid Tumors
Alok Khorana, MD of Cleveland Clinic discusses the skepticism surrounding timing to initiating (TTI) cancer therapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Alok Khorana, MD of Cleveland Clinic gives an overview of the treatment trends for gastrointestinal cancers, which includes the use of adjuvant therapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Daniel A. Goldstein, MD of Davidoff Cancer Center gives an overview of the treatment trends for non-small cell lung cancer for 2017, which include new approvals for immunotherapies. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL
Daniel A. Goldstein, MD of Davidoff Cancer Center discusses the impact of weight-based dosing on patients’ affordability of the drug. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL
Daniel A. Goldstein, MD of Davidoff Cancer Center explains the questions regarding the equivalence of dosing in milligrams versus milligrams per kilograms. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9013: A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer.
Daniel A. Goldstein, MD of Davidoff Cancer Center gives an overview of his presentation, involving dosing of pembrolizumab in non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9013: A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the challenges of the AIM2CERV trial at the 2017 ASCO Annual Meeting in Chicago, IL.
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the take-home message coming out of ASCO 2017, which includes the breakthrough of immunotherapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center explains the importance of targeting HPV-associated cancers. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center explains the goal of the AIM2CERV trial, which is to evaluate whether or not axalimogene filolisbac can prevent or reduce the risk of cervical cancer recurrence after patients received the initial standard of care. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the use of AIM2CERV’s axalimogene filolisbac for the treatment of HPV-associated cancers, including cervical cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center gives an overview of his presentation, AIM2CERV: Global Phase 3 Trial of Advaxis Axalimogene Filolisbac for Cervical Cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the impact of the AIM2CERV study on patients with cervical cancer and on clinical practice. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. discusses the most common questions he has been asked regarding the ENCORE study, which are: what are the characteristics of the patients that went into the study, how long has it been since the patients progressed, and are these patients who initially had a response and then progress? This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. gives an overview of a few presentations that he finds the most promising from the 2017 ASCO Annual Meeting in Chicago, IL.
Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. gives an overview of his presentation, Abstract #9529 ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma, which was discussed at the 2017 ASCO Annual Meeting in Chicago, IL.
Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. discusses the treatment trends in 2017 for advanced melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Krishnansu S. Tewari, MD of University of California, Irvine explains what CA4P is. CA4P is a vascular disrupting agent (VDA), which is thought to work by blocking the blood supply inside the tumor, depriving it of oxygen and nutrients, which leads to cell death. CA4P is being developed by Mateon Therapeutics in South San Francisco, CA. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Krishnansu S. Tewari, MD of University of California, Irvine discusses the most recent results from the FOCUS trial, including the first interim analysis which evaluated the safety of the drug as well as early signs of efficacy. The trial is sponsored by Mateon Therapeutics in South San Francisco, CA This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Krishnansu S. Tewari, MD of University of California, Irvine gives an overview of the FOCUS trial, which is sponsored by Mateon Therapeutics in South San Francisco, CA. The FOCUS trial is a double-blind, randomized, phase 2/3 clinical study evaluating the efficacy and safety of physicians choice chemotherapy plus bevacizumab and CA4P versus physicians choice chemotherapy plus bevacizumab and placebo in patients with platinum-resistant ovarian cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL
Krishnansu S. Tewari, MD of University of California, Irvine discusses the impact of the FOCUS trial on clinical practice, explaining how the trial gives ovarian cancer patients another option for treatment.
Mark Rutstein, Vice President of Oncology Development of Bayer discusses the xofigo injection, a treatment method for patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of three abstracts that discussed the use of regorafenib (stivarga) in advanced colorectal cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract #3567: Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study Abstract #3551: Handfoot skin reaction (HFSR) and outcomes in the phase 3 CORRECT trial of regorafenib for metastatic colorectal cancer (mCRC) Abstract #4078: Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in…
Mark Rutstein, Vice President of Oncology Development of Bayer discusses his take on the treatment trends for 2017 and 2018, which include the growth of immunotherapy and therapy tailored to individual patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Mark Rutstein, Vice President of Oncology Development of Bayer discusses the RIFTOS trial, which focused on the use of sorafenib for thyroid cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract #6084: Interim baseline characteristics from RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC)